Table 4.
Unadjusted and adjusted odds ratio of rapid renal function progression by diabetes mellitus status and baseline systolic blood pressure in stage 3 or 4 chronic kidney disease
| Total | Non-DM | DM | ||||
|---|---|---|---|---|---|---|
| Unadjusted OR (95% CI) | Adjusted ORa (95% CI) | Unadjusted OR (95% CI) | Adjusted ORa (95% CI) | Unadjusted OR (95% CI) | Adjusted ORa (95% CI) | |
| Rapid renal progressionb SBP, mm Hg | ||||||
| 96–110 | 0.58 (0.40–1.00) | 0.56 (0.30–1.03) | 0.50 (0.23–1.09) | 0.42 (0.18–0.99) | 0.64 (0.30–1.37) | 0.83 (0.33–2.04) |
| 111–120 | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group |
| 121–140 | 1.16 (0.83–1.60) | 1.15 (0.79–1.67) | 1.06 (0.68–1.64) | 1.00 (0.62–1.61) | 1.26 (0.77–2.08) | 1.37 (0.76–2.47) |
| >140 | 1.84 (1.34–2.53) | 1.30 (0.89–1.89) | 1.43 (0.92–2.23) | 1.04 (0.64–1.71) | 2.02 (1.25–3.25) | 1.67 (0.93–2.98) |
Abbreviations: CI, confidence interval; DM, diabetes mellitus; OR, odds ratio; SBP, systolic blood pressure.
aFully adjusted model included age, sex, estimated glomerular filtration rate, urine protein–creatinine ratio, hemoglobin, albumin, phosphorus, total cholesterol, C-reactive protein, body mass index, smoking status, baseline congestive heart failure, myocardial infarction, cerebral vascular disease, and the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, alpha-blockers, and diuretics.
bDefined as an estimated glomerular filtration rate slope <−5ml/min/1.73 m2/year.